Pregabalin Capsule
Product Images NDC 71610-925

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-925). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0925 30)

Pregabalin 300 mg oral capsules label showing a 30 capsule count. The label includes storage instructions, manufacturer Aphena Pharma Solutions - Tennessee, LLC, and packager Aphena Pharma in Cookeville, TN. It indicates prescription use only (RX Only) with batch and expiration placeholders.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of pregabalin, showing its molecular composition with key groups including an amino group and a carboxylic acid group attached to a carbon backbone.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo. The chart includes labeled vertical markers highlighting specific percent improvement values.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent improvement in pain from baseline to the percent of patients improved. The graph has two lines: one for Pregabalin 100 mg three times a day and another for placebo, showing patient response distributions across pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, and a placebo group, with lines representing each treatment group's response across a range of pain improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis represents percent of patients improved; the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph depicting the percent of patients improved by percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo, illustrating patient response across varying levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin 07)

Bar chart depicting responder rates (%) from two clinical studies, Study E1 and Study E3, comparing placebo with various dosages of pregabalin. The x-axis lists treatment groups including placebo and different pregabalin doses, while the y-axis shows responder rates as percentages. The chart highlights higher responder rates for pregabalin doses compared to placebo in both studies.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph showing the median percentage change from baseline in seizure reduction versus pregabalin dose in mg/day. It compares data points from four studies labeled E1BD, E2TID, E3BD, and E3TID, each represented with different markers. Significant p-values are indicated at various doses.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar chart comparing responder rates (%) among three groups: placebo with 22.6% (n=93), pregabalin 2.5 mg/kg/day with 29.1% (n=103), and pregabalin 10 mg/kg/day with 40.6% (n=96). The vertical axis represents responder rate percentages from 0 to 60%.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. Four lines represent different daily doses of Pregabalin (800 mg, 450 mg, 300 mg) and placebo, showing comparative patient improvement trends over a range of pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin 11)

A line graph comparing the estimated percentage of subjects without LTR (Loss of Therapeutic Response) over a period of 180 days for Pregabalin versus placebo. The vertical axis shows the estimated percentage of subjects without LTR, and the horizontal axis shows the number of days. Two lines represent the groups: solid for Pregabalin and dashed for placebo.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line chart comparing the percent of subjects improved over baseline to week 12 BOCF on the x-axis and percent of subjects improved on the y-axis. Two lines represent Pregabalin and Placebo, showing higher improvement percentages for Pregabalin throughout the time course.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percent of subjects improved from baseline to Week 16 BOCF between Pregabalin and placebo. The x-axis represents percent improvement, and the y-axis represents the percent of subjects improved. Two lines indicate treatment effects, a solid line for Pregabalin and a dashed line for placebo, showing greater improvement with Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.